Saturday, July 11, 2026

pharma · Peripheral T Cell Lymphoma

Zhao Weili

Zhao Weili drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
1
Drugs
3
Patents
0
Intelligence · Drug Pipeline

Zhao Weili pipeline

Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Zhao Weili drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

3 compounds
  1. Development asset linked to Zhao Weili in public FDA and regional records.

  2. Development asset linked to Zhao Weili in public FDA and regional records.

  3. Development asset linked to Zhao Weili in public FDA and regional records.